Remdesivir Potentially Most Effective For Coronavirus: China Investigator
Although AbbVie’s Kaletra has shown promising efficacy in COVID-19 patients, Gilead’s remdesivir has stronger antiviral activity, says one Chinese investigator leading studies in the coronavirus outbreak epicenter Wuhan.
You may also be interested in...
With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
Analysts see NIAID’s placebo-controlled data as more important than Gilead’s open-label data. Quick emergency use authorization by FDA is possible, but the US agency has not confirmed EUA.
Gene therapies for conditions ranging from hemophilia to retinal diseases are blossoming in China and the race in which the winner may take all is on. Driven by ready investors, the field is on the cusp of becoming the latest innovation battleground in the country, while some developers are already moving ahead in the US.